Medical Developments International Limited announced that despite the fact that during fiscal 2018 Penthrox has been approved for sale in 15 additional countries including Canada, Germany, Mexico, Sweden and numerous other European countries, the upside from this global expansion will not be seen until fiscal 2019. Accordingly, MVP advise that gross revenue for fiscal 2018 will likely be flat or slightly down on fiscal 2017. Underlying profit for fiscal 2018 is expected to be $0.3 million because of, the company continues to invest in the required infrastructure ahead of the anticipated roll out of Penthrox across Europe, Mexico, Canada and the Middle East.